Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

Aichi Cancer Center Hospital, Nagoya

Fujita Health University Hospital, Toyoake

Kanagawa Cancer Center, Yokohama

Kurashiki Central Hospital, Kurashiki

Kansai Medical University Hirakata Hospital, Hirakata

Osaka International Cancer Institute, Osaka

National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai-shi

Kinki University Hospital, Sayama

Shizuoka Cancer Center, Sunto-gun

Jichi Medical University Hospital, Shimotsuke

Juntendo University Hospital, Bunkyo-ku

National Hospital Organization Iwakuni Clinical Center, Iwakuni

National Hospital Organization, Yamaguchi-Ube Medical Center, Ube

The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo

National Cancer Center, Tokyo

Toyama Prefectural Central Hospital, Toyama